News

The FDA has granted a fast track designation to a novel CCR5 antagonist, leronlimab (PRO 140), for use in combination with carboplatin to treat patients with CCR5-positive metastatic triple-negative breast cancer.

Mirvetuximab soravtansine, an antibody-drug conjugate, led to a favorable benefit-risk profile in patients with folate receptor alpha–positive ovarian cancer according to a comprehensive analysis of the phase III FORWARD trial.

Andre Goy, MD, highlighted major controversies being investigated in the field of MCL in terms of patient subgroups and optimal management of each subpopulation.

In a preliminary analysis of a phase II trial, the radiolabeled small molecule, ¹⁷⁷LuPSMA-617, demonstrated a biochemical progression-free survival of 4 months in a cohort of 64 men with metastatic castrate-resistant prostate cancer.

A phase III clinical trial evaluating cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with previously untreated advanced renal cell carcinoma has been initiated, according to Exelixis, the developer of cabozantinib.

In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD.

Ado-trastuzumab emtansine has been approved by the FDA for use as an adjuvant treatment option for patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab and chemotherapy.

The combination of atezolizumab and cobimetinib failed to demonstrate a significant benefit compared with regorafenib in a phase III study of heavily pretreated patients with advanced colorectal cancer.

In an interview with Targeted Oncology, Alexander E. Perl, MD, discussed the final results from the ADMIRAL trial and the impact these results have on practice.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, discussed the diagnostic workup and treatment considerations he makes when seeing a patient with Hodgkin lymphoma in the clinic.

The NCODA Patient Satisfaction Surveys&nbsp;aim to evaluate overall satisfaction with the pharmacy model from which patients receive therapy, convenience, timing to receive drug, interaction with staff, and financial assistance if available.

Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line&nbsp;treatment of adult patients with <em>IDH1</em>-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are &ge;75 years old or are ineligible to receive intensive chemotherapy.

A new single-center report has found that the results of next-generation sequencing&ndash;based molecular profiling for non&ndash;GI stromal tumor sarcomas provided information used to effectively guide clinical management.

Combining&nbsp;lenalidomide with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Michael J. Overman, MD,&nbsp;discusses the combination regimen of nivolumab and ipilimumab in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Daratumumab salvage therapy demonstrated a 1-year overall survival rate of&nbsp;90.9% in patients with multiple myeloma who&nbsp;relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies,&nbsp;according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.

The National Community Oncology Dispensing Association has announced the addition of hematologist and medical oncologist Barry D. Brooks, MD, to its executive council in April.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;April 2019, including several new approvals, a priority review, breakthrough designation, and more.

The PDGFR&alpha; antagonist olaratumab (Lartruvo) will be withdrawn from the market for the treatment of patients with advanced soft tissue sarcoma due to disappointing findings in the phase III ANNOUNCE trial, according to Eli Lilly and Company.

Apalutamide has been submitted for FDA approval for the treatment of patients with metastatic castration-sensitive prostate cancer.

According to a single-institution retrospective study recently published in&nbsp;<em>Clinical Lymphoma, Myeloma &amp; Leukemia,&nbsp;</em>minimally toxic first-line therapies may be beneficial in early extranodal follicular lymphoma compared with observation.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has been launched by Roche to help identify&nbsp;<em>HER2</em> amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

A new drug application seeking the approval of darolutamide as a treatment for patients with nonmetastatic castration-resistant prostate cancer has been granted a priority review designation by the FDA.

David R. Gandara, MD, discusses the treatment decisions he makes and the data that support his recommendations for treating patients with non&ndash;small cell lung cancer

Significantly higher response rates were seen in patients with&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor &nbsp;before receiving lorlatinib and who harbored an&nbsp;<em>ALK&nbsp;</em>resistance mutation compared with those who did not have an&nbsp;<em>ALK&nbsp;</em>mutation.

Clinical outcomes were consistent among transplant-eligible patients with mantle cell lymphoma, regardless of which chemoimmunotherapy induction treatment was administered to the patient.

Treatment with&nbsp;tagraxofusp led to a high rate of responses in patients with&nbsp;blastic plasmacytoid dendritic cell neoplasm regardless of whether patients had received prior treatment or not, findings from a nonrandomized phase II trial demonstrated.

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

The first patient has been dosed in a phase III clinical trial investigating the addition of uproleselan (GMI-1271) to standard 7+3 chemotherapy in older patients with previously untreated acute myeloid leukemia.

Kristen Ciombor, MD, MSCI,&nbsp;discusses the promise of liquid biopsies in the rapidly evolving mCRC paradigm and the potential implications of the COLOMATE trial.